Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22096311 | 0.73 | ACLY (0.35) | ACLYCNR1CNR2ESR1 | |
| SCHEMBL20327695 | 0.73 | ACLY (0.32) | ACLY | |
| SCHEMBL12756348 | 0.71 | ESR1 (0.35) | ESR1 | |
| SCHEMBL26898334 | 0.71 | — | — | |
| SCHEMBL23219398 | 0.70 | ACLY (0.36) | ACLYCNR1CNR2ESR1 | |
| SCHEMBL22676995 | 0.70 | ESR1 (0.32) | ESR1 | |
| SCHEMBL18735598 | 0.70 | ACLY (0.34) | ACLYCNR1CNR2ESR1PRMT6 | |
| SCHEMBL22147282 | 0.68 | PON1 (0.40) | ACLYCNR1CNR2ESR1 | |
| SCHEMBL26746359 | 0.68 | CYP1A1 (0.35) | ACLYCNR1CNR2ESR1 | |
| SCHEMBL19750753 | 0.68 | CCR9 (0.33) | ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230157999-A1 | PYRANO[4,3-B]INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-05-25 | — | — | US | disclosed |
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190282535-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10335388-B2 | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190048421-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-02-14 | — | — | US | disclosed |
| US-20180140569-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282535-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | ACLY 524/4885CNR1 2910/4885CNR2 1211/4885 |
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | HIF1AN, HIF1A, EGLN2 | ACLY 564/4885CNR1 2933/4885CNR2 1312/4885 |
| US-20230157999-A1 | PYRANO[4,3-B]INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | ACLY 1217/4885CNR1 2936/4885CNR2 4440/4885 |
| US-20190048421-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | HIF1AN, HIF1A, EGLN2 | ACLY 1011/4885CNR1 3806/4885CNR2 2236/4885 |
| US-20180140569-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | ACLY 440/4885CNR1 2770/4885CNR2 1014/4885 |
| US-10335388-B2 | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof | HIF1AN, HIF1A, EGLN2 | ACLY 440/4885CNR1 2770/4885CNR2 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.